<img src="https://ml-eu.globenewswire.com/Resource/Download/52d47424-fffd-4350-8392-c23f357f1f77?size=2" nborder="0" align="left" hspace="5" vspace="5" title="New Cleo.jpg" alt="Newcleo SA"/>NEW YORK, Sept. 17, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- NewHold Investment Corp. III (NASDAQ: NHIC, “NewHold”), a publicly traded special purpose acquisition company, today announced that its shareholders have approved all proposals related to the previously announced business combination (the “Business Combination”) with newcleo plc (“newcleo”), a public limited company incorporated under the laws of England and Wales (f/k/a NewCleo Ltd., a private limited company incorporated under the laws of England and Wales) at NewHold’s Extraordinary General Meeting held today, Thursday, September 17, 2026. Approximately 93.4% of the votes cast at the meeting on the Business Combination proposal were in favor of the combination with newcleo, representing approximately 72.4% of NewHold’s outstanding shares. The formal results of the vote will be included on a Form 8-K to be filed with the U.S. Securities and Exchange Commission (the “SEC”). The closing of the Business Combination is anticipated to occur on or about Monday, September 21, 2026, upon satisfaction of customary closing conditions. Following the closing, the combined company will operate as newcleo plc (“newcleo”), and its shares of common stock and warrants are expected to trade on the Nasdaq Stock Market LLC under the symbols “NWCL” and “NWCLW,” respectively, beginning on or about Tuesday, September 22, 2026. About newcleo newcleo is an innovative nuclear energy company developing advanced modular reactors (AMRs) cooled by liquid lead, and facilities to produce nuclear fuel from recycled nuclear waste, with the goal of delivering abundant, competitive, low-carbon energy. The company was founded by physicist-entrepreneur Stefano Buono following the USD $3.9 billion sale of his previous venture – Nasdaq-listed nuclear medicine company Advanced Accelerator Applications – to Novartis. With approximately USD $800 million in private funding, and more than 900 highly skilled employees across Europe and the United States, the company has built a network of over 100 industry partnerships and supports its growth through the targeted acquisition and vertical integration of key companies in the nuclear supply chain. For more information visit <a href="https://www.globenewswire.com/Tracker?data=L7BcSWvLU2IRAXlMeFRrfMyL8kGsHQLE_SzijYv1pir6CH_hOBCE5-8WL3bscz3aSZbwE6kMBprMNLX1-9TwS7T772cw0dzE9SMBvxuqZsY=" rel="nofollow" target="_blank" title="www.newcleo.com">www.newcleo.com</a>. About NewHold Investment Corp III NewHold Investment Corp III is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While NewHold may pursue a business combination in any sector, NewHold’s primary focus is on growing industrial and business services companies. NewHold is led by an experienced management team with Kevin Charlton as Chief Executive Officer, Samy Hammad as President and Chief Operating Officer and Polly Schneck as Chief Financial Officer. For more information visit <a href="https://www.globenewswire.com/Tracker?data=4lasEjK44m4rd1nxfxfiPEhZDXu9mRYn2Td19pUmrFnsPIUelAcf4NN-VOy5IJdqDtCXng6fPCMrIDxbohEo62u2oY5QzYOS54qdAVnuakY=" rel="nofollow" target="_blank" title="">https://nhicspac.com</a>. No Offer or Solicitation This communication is for informational purposes only and is not a proxy statement or solicitation of a proxy, consent or authorization, with respect to any securities or in respect of the Proposed Transactions and shall not constitute an offer to sell or exchange, or a solicitation of an offer to buy or exchange the securities of NewHold or newcleo, or any commodity or instrument or related derivative, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1934, as amended (the “Securities Act”) or an exemption therefrom. Investors should consult with their counsel as to the applicable requirements for a purchaser to avail itself of any exemption under the Securities Act. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of the U.S. federal securities laws with respect to the proposed business combination between NewHold and newcleo (the “Business Combination”), the private placements of securities in connection with the Business Combination (the “Private Placement Transactions”), and the other transactions contemplated by the Business Combination Agreement (together with the Business Combination and the Private Placement Transactions, the “Proposed Transactions”) and the parties thereto. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding the Business Combination between NewHold and newcleo; the anticipated benefits and timing of the transaction; expected trading of the combined company’s securities on Nasdaq; the completion of investments from certain institutional investors; the expected amount of gross proceeds from any investments or other financing arrangements; the anticipated use of proceeds from such investments or financing arrangements; newcleo’s development and commercialization of its lead-cooled fast reactor technology, mixed-oxide fuel capabilities and related products and services; the expected timing, cost, performance and benefits of newcleo’s demonstration projects, fuel facilities, reactor deployments and licensing activities; newcleo’s ability to execute its business strategy, develop its technology, obtain required regulatory approvals, permits and licenses, enter into commercial arrangements, achieve its market opportunity and positioning and support the growth of advanced nuclear energy; newcleo’s expectations regarding strategic partnerships, customer demand, project pipeline, revenue streams, capital expenditures and financing needs; and other statements regarding management’s intentions, beliefs, or expectations with respect to the combined company’s future performance, are forward-looking statements. Forward-looking statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “develop,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on the current expectations and assumptions of NewHold and newcleo and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could delay or prevent the consummation of the proposed Business Combination; (2) the outcome of any legal proceedings that may be instituted against NewHold, newcleo, the combined company, or others following the announcement of the Proposed Transactions; (3) the inability to complete the Business Combination due to failure to satisfy closing conditions; (4) the inability to complete any Private Placement Transactions or other financing arrangements on the expected terms, or at all; (5) changes to the structure, timing or terms of the Proposed Transactions; (6) the ability of the combined company to meet applicable listing standards or to maintain the listing of its securities following the closing of the Business Combination; (7) the risk that the announcement and consummation of the transaction disrupts current plans, operations, relationships with customers, suppliers, regulators, partners and employees, or newcleo’s ability to retain key personnel; (8) the ability to recognize the anticipated benefits of the Business Combination, including the ability to fund and execute newcleo’s technology development, licensing, manufacturing, fuel supply and commercialization plans; (9) risks related to newcleo’s early stage of development, limited operating history and expected need for substantial additional capital to develop, license, construct and commercialize its technologies and facilities; (10) risks related to the development, demonstration, licensing and deployment of advanced nuclear technologies, including newcleo’s lead-cooled fast reactor technology and mixed-oxide fuel strategy; (11) risks related to technical performance, engineering, manufacturing, construction, supply chain, fuel availability, cost estimates, project delays, cost overruns, corrosion, materials performance, safety, reliability and other development or operational challenges; (12) risks related to obtaining, maintaining or complying with required regulatory approvals, permits, authorizations, licenses and export control approvals in the United States, the United Kingdom, France, Italy, the European Union and other jurisdictions in which newcleo may operate; (13) changes in market, regulatory, political and economic conditions affecting the nuclear energy industry, advanced reactor development, energy markets, capital markets and infrastructure financing; (14) the costs related to the Proposed Transactions and those arising as a result of becoming a public company; (15) the level of redemptions of NewHold’s public shareholders, which may reduce the amount of cash available to the combined company and may reduce the public float of, reduce the liquidity of the trading market of, and/or maintain the quotation, listing or trading of securities of NewHold or newcleo; (16) risks related to increased competition in the industries in which newcleo will operate; (17) risks related to changes in U.S. or foreign laws and regulations applicable to nuclear energy, export controls, sanctions, trade restrictions, foreign investment, environmental protection, health and safety, securities and public company reporting; (18) the possibility that the combined company may be adversely affected by competitive factors, investor sentiment, litigation, cybersecurity incidents, geopolitical developments or other macroeconomic conditions; (19) the risk of being considered to be a “former shell company” by any stock exchange on which newcleo securities will be listed or by the SEC, which may impact the ability to list newcleo’s securities and restrict reliance on certain rules or forms in connection with the offering, sale or resale of securities; and (20) other risks detailed from time to time in NewHold’s filings with the SEC, including the Registration Statement on Form F-4 filed by newcleo (the “Registration Statement”) with the SEC, which includes a proxy statement of NewHold and a prospectus of newcleo (the “Proxy Statement/Prospectus”) and related documents filed or to be filed in connection with the Business Combination. The foregoing list of risk factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of NewHold’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on April 1, 2026, the Registration Statement and Proxy Statement/Prospectus, and other documents filed by NewHold and newcleo from time to time with the SEC, as well as the list of risk factors included herein. These filings do or will identify and address other important risks and uncertainties that could cause actual results to differ materially from those contained in the forward-looking statements. Additional risks and uncertainties not currently known or that are currently deemed immaterial may also cause actual results to differ materially from those expressed or implied by such forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and none of the parties or any of their representatives assumes any obligation or intends to update or revise these forward-looking statements, each of which is made only as of the date of this press release. Contacts For investors: <a href="https://www.globenewswire.com/Tracker?data=OjHojc-p7OJVee50KxQr8HA_8toK2X44lrHBz115zmFve-9NJqaInTQw345_Ko27ENe3vcfq0jW9TDVdXaUjbUQ0zxZxrJQIQCZCoZ1oG9I=" rel="nofollow" target="_blank" title="">newcleo@icrinc.com</a> For media: European media inquiries <a href="https://www.globenewswire.com/Tracker?data=35kBHbyJIKSwptlKRP4DlfKUyWmWHv7vNc7fzTr2gH2p9mrmAa0qoqPh2DXgVMcuvQ1vURq8YdgZ-uDblpe8k9TSmN08UDRhvg6EzKd-fbM=" rel="nofollow" target="_blank" title="media@newcleo.com">media@newcleo.com</a> U.S. media inquiries <a href="https://www.globenewswire.com/Tracker?data=OjHojc-p7OJVee50KxQr8HA_8toK2X44lrHBz115zmGmIWn-3NxeWkgDJluZcVS6n55jrUNN48yf8mj8n0pK_YAhvGkt5cdehflA50t5puU=" rel="nofollow" target="_blank" title="">newcleo@icrinc.com</a> <img alt="" src='https://ml-eu.globenewswire.com/media/YjJkYTgyMzAtODlkMC00ODIzLTg2MDItNjRjOTAzMWRhODkyLTEzMjAwMTQtMjAyNi0wOS0xNy1lbg==/tiny/Newcleo-SA.png' referrerpolicy='no-referrer-when-downgrade' />

NewHold Investment Corp. III Shareholders Approve Business Combination with newcleo plc

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn